stockportfolio.pro
NBIX vs SOLV: Which Stock Is the Better Buy?
Neurocrine Biosciences, Inc. and Solventum Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — NBIX vs SOLV, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Neurocrine Biosciences, Inc. (NBIX) | Solventum Corporation (SOLV) | |
|---|---|---|
| Market cap | $16.3B | $14.1B |
| Revenue (latest FY) | $2.86B | $8.32B |
| Net income (latest FY) | $478.60M | $1.56B |
| Revenue growth (5y CAGR) | 22.3% | 0.8% |
| Net margin | 16.7% | 18.7% |
| Return on equity | 14.7% | 30.8% |
| P/E ratio | 25.0 | 10.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 8 | 4 |
| Positive free cash flow | Yes | No |
See the full NBIX vs SOLV breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open NBIX's full financials → Open SOLV's full financials →More comparisons
Frequently asked questions
Which is bigger, NBIX or SOLV?
Neurocrine Biosciences, Inc. is larger by market capitalization — $16.3B versus $14.1B.
Which grows faster, NBIX or SOLV?
Over the last five fiscal years, Neurocrine Biosciences, Inc. grew revenue faster — 22.3%/yr versus 0.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.